COMMUNIQUÉS West-GlobeNewswire

OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann
08/04/2024
PRESS RELEASE OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann Oxford, United Kingdom – 8 th April 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology [...]
Curium Plans to Significantly Expand Lutetium-177 Capacity and Pet Footprint With Agreement to Acquire Eczacibaşi-Monrol
08/04/2024
The proposed acquisition of Eczacıbaşı-Monrol will: Build on existing partnership in Lu-177 creating a leading manufacturer of the isotope Add 12 PET sites to Curium’s existing network in geographies where Curium is not [...]
Nxera Pharma joins the World Orphan Drug Alliance
08/04/2024
Nxera Pharma to represent WODA in Japan and South Korea WODA offers a ‘one-stop’ solution for biopharma companies seeking to commercialize rare or orphan medicines across global markets Tokyo, Japan and Cambridge, UK, 8 [...]
SIRONA BIOCHEM Corporate Update April 2024
08/04/2024
VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“ Sirona ” or the “ Company ”) provides the following update: Dear shareholders, We are pleased [...]
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
08/04/2024
Planegg/Martinsried, April 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid [...]
Glycotope to present platform approach for development of anti-GlycoTarget antibodies at 2024 AACR Meeting
08/04/2024
Glycotope to present platform approach for development of anti-GlycoTarget antibodies at 2024 AACR Meeting Berlin, Germany, 08 April, 2024 – Glycotope GmbH, a biotechnology company utilizing a proprietary platform [...]
Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
08/04/2024
This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Leiden, the Netherlands, April 8, 2024: Pharming Group N.V. (“Pharming” or “ [...]
Evaxion et un collaborateur anonyme annoncent des résultats encourageants concernant les antigènes du vaccin EVX-B1 contre l'infection à staphylocoque doré
08/04/2024
Evaxion et son collaborateur ont testé les antigènes du vaccin conçus par Evaxion contre le staphylocoque doré sur un modèle animal cliniquement pertinent présentant une infection du site opératoire. Les antigènes du [...]
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
08/04/2024
Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R mutation, a setting [...]
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
07/04/2024
RP1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate of nearly 22 percent in evaluable patients SAN DIEGO, April 07, 2024 (GLOBE NEWSWIRE) -- [...]
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
07/04/2024
WATERTOWN, Mass. and GOSSELIES, Belgium, April 07, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new [...]
iTeos présente les données précliniques de l’EOS-984 démontrant la restauration de l’activité des cellules T à partir de la suppression de l’adénosine lors de la réunion annuelle de l’Association américaine pour la recherche sur le cancer 2024
07/04/2024
WATERTOWN, Massachusetts et GOSSELIES, Belgique, 07 avr. 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS), une société biopharmaceutique au stade clinique pionnière dans la découverte et le [...]
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
07/04/2024
Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) TARRYTOWN, N.Y., April 07, 2024 (GLOBE NEWSWIRE) -- Regeneron [...]
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
07/04/2024
Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspecific T cell responses up to three [...]
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
07/04/2024
- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression - The data [...]
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
07/04/2024
SHANGHAI, China, April 07, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery [...]
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
06/04/2024
V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant LDL-C reduction vs. [...]
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
06/04/2024
-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels -- -- Lp(a) Results Published Simultaneously in the Journal of the American College of Cardiology [...]
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
06/04/2024
Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p<0.0001) through six months, with clinically meaningful reductions of 24-30% achieved with a [...]

Pages